Fesoterodine "add-on" Male Overactive Bladder Study
Completed · Phase 3 · Has a placebo group
Conditions studied: Overactive Bladder Syndrome
In brief
To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.
Key facts
- Study ID
- NCT00546637
- Run by
- Pfizer
- People needed
- 947
- Starts
- 2007-11-01
- Expected to finish
- 2009-02-01
- Last updated by the study team
- 2011-02-18
Who can join
Age: 40 and older. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Men aged 40 years and above.
- On a stable and well-tolerated dose of an alpha-blocker prescribed for LUTS for at least 6 weeks prior to screening (Visit 1).
- Persistent symptoms of OAB with urinary frequency >=8 times/24 hours and micturition-related urgency episodes >=3 episode/24 hours.
You may not qualify if…
- Contraindication to fesoterodine (antimuscarinics).
- Previous history of acute urinary retention requiring catheterization or severe voiding difficulties in the judgment of the investigator, prior to baseline.
- Unable to follow the study procedures, including completion of self-administered bladder diary and patient reported outcome questionnaires.
Where it is running
- Pfizer Investigational Site — Gilbert, Arizona, United States
- Pfizer Investigational Site — Gilbert, Arizona, United States
- Pfizer Investigational Site — Litchfield Park, Arizona, United States
- Pfizer Investigational Site — Mesa, Arizona, United States
- Pfizer Investigational Site — Phoenix, Arizona, United States
- Pfizer Investigational Site — Tucson, Arizona, United States
- Pfizer Investigational Site — La Mesa, California, United States
- Pfizer Investigational Site — Newport Beach, California, United States
- Pfizer Investigational Site — San Bernardino, California, United States
- Pfizer Investigational Site — San Diego, California, United States
- Pfizer Investigational Site — San Diego, California, United States
- Pfizer Investigational Site — Aurora, Colorado, United States
- Pfizer Investigational Site — Denver, Colorado, United States
- Pfizer Investigational Site — Jupiter, Florida, United States
- Pfizer Investigational Site — Orange City, Florida, United States
- Pfizer Investigational Site — West Palm Beach, Florida, United States
- Pfizer Investigational Site — Dunwoody, Georgia, United States
- Pfizer Investigational Site — Evansville, Indiana, United States
- Pfizer Investigational Site — Jeffersonville, Indiana, United States
- Pfizer Investigational Site — Newburgh, Indiana, United States
- Pfizer Investigational Site — Des Moines, Iowa, United States
- Pfizer Investigational Site — Iowa City, Iowa, United States
- Pfizer Investigational Site — Baltimore, Maryland, United States
- Pfizer Investigational Site — Owings Mills, Maryland, United States
- Pfizer Investigational Site — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.